| Literature DB >> 31434007 |
Seong Gak Jeon1, Sang Bum Hong1, Yunkwon Nam1, Jungyeon Tae1, Anji Yoo1, Eun Ji Song1, Kun Il Kim1, Dongje Lee1, Junyong Park1, Sang Min Lee2, Jin-Il Kim3, Minho Moon4.
Abstract
Ghrelin, which has many important physiological roles, such as stimulating food intake, regulating energy homeostasis, and releasing insulin, has recently been studied for its roles in a diverse range of neurological disorders. Despite the several functions of ghrelin in the central nervous system, whether it works as a therapeutic agent for neurological dysfunction has been unclear. Altered levels and various roles of ghrelin have been reported in Alzheimer's disease (AD), which is characterized by the accumulation of misfolded proteins resulting in synaptic loss and cognitive decline. Interestingly, treatment with ghrelin or with the agonist of ghrelin receptor showed attenuation in several cases of AD-related pathology. These findings suggest the potential therapeutic implications of ghrelin in the pathogenesis of AD. In the present review, we summarized the roles of ghrelin in AD pathogenesis, amyloid beta (Aβ) homeostasis, tau hyperphosphorylation, neuroinflammation, mitochondrial deficit, synaptic dysfunction and cognitive impairment. The findings from this review suggest that ghrelin has a novel therapeutic potential for AD treatment. Thus, rigorously designed studies are needed to establish an effective AD-modifying strategy.Entities:
Keywords: Alzheimer’s disease; Amyloid beta; Ghrelin; Mitochondrial deficits; Neuroinflammation; Tau
Mesh:
Substances:
Year: 2019 PMID: 31434007 DOI: 10.1016/j.arr.2019.100945
Source DB: PubMed Journal: Ageing Res Rev ISSN: 1568-1637 Impact factor: 10.895